Last reviewed · How we verify
NCT06099509
Self-Administered 2-Hour Oral Glucose Tolerance Test
NA trial testing Self-administered oral glucose tolerance test in Gestational Diabetes in 200 participants. Completed in 1 May 2025.
28 February 2025
Quick facts
| Lead sponsor | Prisma Health-Upstate |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 200 |
| Start date | 2 November 2023 |
| Primary completion | 28 February 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Self-administered oral glucose tolerance test
Conditions studied
- Gestational Diabetes — all drugs for Gestational Diabetes →
- Postpartum Disorder — all drugs for Postpartum Disorder →
- Gestational Diabetes Mellitus in Pregnancy — all drugs for Gestational Diabetes Mellitus in Pregnancy →
Sponsor
Prisma Health-Upstate — full company profile →
Who can join
18 and older, female only, with Gestational Diabetes or Postpartum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized controlled trial is to evaluate whether self-administered postpartum diabetes screening tests in patients with gestational diabetes improves screening completion rates. The primary question it aims to answer is: 1\. Does a self-administered 75-gram oral glucose tolerance test with virtual follow-up visit increase the rate of postpartum diabetes screening within 12 weeks of delivery?
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06099509
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gestational Diabetes
Currently open trials in the same condition.
- NCT07171684 — Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) · NA · recruiting
- NCT07314944 — Maternal Sleep and Lifestyle, Metabolic Health, and Perinatal Outcomes in Gestational Diabetes · recruiting
- NCT06571487 — Growth Hormone Resistance of Beta-cells · recruiting
- NCT07336914 — Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes · NA · recruiting
- NCT07174245 — Pregnancy and Postpartum CGM in GDM · recruiting
Other Prisma Health-Upstate trials
Trials by the same sponsor.
- NCT07202039 — Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine · NA · not yet recruiting
- NCT07375212 — VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure · Phase 4 · withdrawn
- NCT07102615 — Intracervical Vasopressin · Phase 4 · recruiting
- NCT07101250 — Preoperative Acetazolamide · Phase 4 · recruiting
- NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06099509 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prisma Health-Upstate
- Last refreshed: 2 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06099509.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing